Abstract:In this study we exploit a large panel of gastric cancer (GC) cell lines and powerful (phospho)proteomic workflows to provide the most comprehensive characterization of the GC proteome to date. The data are used to generate novel subclassifications and we identify, and then validate through functional analyses and interrogation of publicly available data, kinase targets for broad or precision GC treatment. Different molecular classifications for gastric cancer (GC) have been proposed based on multi‐omics platforms with the long‐term goal of improved precision treatment. However, the GC (phospho)proteome remains incompletely characterized, particularly at the level of tyrosine phosphorylation. In addition, previous multiomics‐based stratification of patient cohorts has lacked identification of corresponding cell line models and comprehensive validation of broad or subgroup‐selective therapeutic targets. To address these knowledge gaps, we applied a reverse approach, undertaking the most comprehensive (phospho)proteomic analysis of GC cell lines to date and cross‐validating this using publicly available data. Mass spectrometry (MS)‐based (phospho)proteomic and tyrosine phosphorylation datasets were subjected to individual or integrated clustering to identify subgroups that were subsequently characterized in terms of enriched molecular processes and pathways. Significant congruence was detected between cell line proteomic and specific patient‐derived transcriptomic subclassifications. Many protein kinases exhibiting 'outlier' expression or phosphorylation in the cell line dataset exhibited genomic aberrations in patient samples and association with poor prognosis, with casein kinase I isoform delta/epsilon (CSNK1D/E) being experimentally validated as potential therapeutic targets. Src family kinases were predicted to be commonly hyperactivated in GC cell lines, consistent with broad sensitivity to the next‐generation Src inhibitor eCF506. In addition, phosphoproteomic and integrative clustering segregated the cell lines into two subtypes, with epithelial–mesenchyme transition (EMT) and proliferation‐associated processes enriched in one, designated the EMT subtype, and metabolic pathways, cell–cell junctions, and the immune response dominating the features of the other, designated the metabolism subtype. Application of kinase activity prediction algorithms and interrogation of gene dependency and drug sensitivity databases predicted that the mechanistic target of rapamycin kinase (mTOR) and dual specificity mitogen‐activated protein kinase kinase 2 (MAP2K2) represented potential therapeutic targets for the EMT and metabolism subtypes, respectively, and this was confirmed using selective inhibitors. Overall, our study provides novel, in‐depth insights into GC proteomics, kinomics, and molecular taxonomy and reveals potential therapeutic targets that could provide the basis for precision treatments.

Phosphoproteomics Enables Molecular Subtyping and Nomination of Kinase Candidates for Individual Patients of Diffuse-Type Gastric Cancer.

Proteome‐based molecular subtyping and therapeutic target prediction in gastric cancer

A Proteomic Landscape of Diffuse-Type Gastric Cancer

Profiling Kinase Activities for Precision Oncology in Diffuse Gastric Cancer

Molecular Subtyping of Cancer and Nomination of Kinase Candidates for Inhibition with Phosphoproteomics: Reanalysis of CPTAC Ovarian Cancer

Phosphoproteomic subtyping of gastric cancer reveals dynamic transformation with chemotherapy and guides targeted cancer treatment

Abstract 5142: Proteome-wide Analysis Identifies Three Subgroups of Diffuse-Type Gastric Cancer

Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil.

Proteomics Provides Individualized Options of Precision Medicine for Patients with Gastric Cancer

Protein Classification of Diffuse-Type Gastric Cancer Using Formalin-Fixed Paraffin-Embedded Samples

Dissecting gastric cancer heterogeneity and exploring therapeutic strategies using bulk and single-cell transcriptomic analysis and experimental validation of tumor microenvironment and metabolic interplay

Proteogenomic Characterization of Human Early-Onset Gastric Cancer

Proteomic and Metabolic Signaling Pathways in Different Prognosis of Gastric Cancer.

Molecular Characterization and Clinical Relevance of Metabolic Signature Subtypes in Gastric Cancer

Identification of angiogenesis-related subtypes and risk models for predicting the prognosis of gastric cancer patients

Molecular classification reveals the diverse genetic and prognostic features of gastric cancer: A multi-omics consensus ensemble clustering

Integrated Proteome and Phosphoproteome Analysis of Gastric Adenocarcinoma Reveals Molecular Signatures Capable of Stratifying Patient Outcome.

Identification of Key Genes and Signaling Pathways Associated with the Progression of Gastric Cancer

Development of a Streamlined NGS-based TCGA Classification Scheme for Gastric Cancer and Its Implications for Personalized Therapy

Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes

Molecular classification reveals the diverse genetic features and prognosis of gastric cancer: a multi-omics consensus ensemble clustering